Trial · NCT02098993

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993, Phase 2, Terminated, Craig Seaman; results first posted 2019-07-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome. Trials, record NCT02098993. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02098993

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
NCT number: NCT02098993
Status: Terminated
Phases: Phase 2
Enrollment: 7 participants, actual
Lead sponsor: Craig Seaman
Conditions: Acute Chest Syndrome, Sickle Cell Disease
Interventions: Unfractionated heparin
First posted: 2014-03-28
Last updated: 2019-07-16
Results first posted: 2019-07-16

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Time to Hospital Discharge	Until hospital discharge	Duration of hospitalization
Secondary	Duration of Hypoxemia Assessed by Arterial Oxygen Saturation	7 days	Arterial oxygen saturation less than 90%
Secondary	Duration of Fever Assessed by Body Temperature	7 days	Body temperature greater than or equal to 38.0 degrees Celsius
Secondary	Duration of Leukocytosis Assessed by White Blood Cell Count	7 days	White blood cell count greater than 10,000 per liter
Secondary	Duration of Moderate to Severe Pain Assessed by Visual Analog Scale for Pain	7 days	Score of 4 or greater on the Visual Analog Scale for pain
Secondary	Opioid Administration Per Participant	7 days	Total dose of opioids per participant
Secondary	Units of Red Blood Cells Administered	7 days	Total number of units of red blood cells
Secondary	Percentage of Participants Transferred to Intensive Care Unit	7 days
Secondary	Percentage of Participants Requiring Mechanical Ventilation	7 days
Secondary	Percentage of Participants Experiencing Multiorgan Dysfunction Syndrome	7 days	Acute development of 2 or more organs or organ systems unable to maintain homeostasis in a critically ill individual

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Time to Hospital Discharge	Until hospital discharge	hours	MEAN
SECONDARY	Duration of Hypoxemia Assessed by Arterial Oxygen Saturation	7 days	hours	MEAN
SECONDARY	Duration of Fever Assessed by Body Temperature	7 days	hours	MEAN
SECONDARY	Duration of Leukocytosis Assessed by White Blood Cell Count	7 days	hours	MEAN
SECONDARY	Duration of Moderate to Severe Pain Assessed by Visual Analog Scale for Pain	7 days	hours	MEAN
SECONDARY	Opioid Administration Per Participant	7 days	mg	MEAN
SECONDARY	Units of Red Blood Cells Administered	7 days	units	NUMBER
SECONDARY	Percentage of Participants Transferred to Intensive Care Unit	7 days	percent of participants	NUMBER
SECONDARY	Percentage of Participants Requiring Mechanical Ventilation	7 days	percent of participants	NUMBER
SECONDARY	Percentage of Participants Experiencing Multiorgan Dysfunction Syndrome	7 days	percent of participants	NUMBER

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Time to Hospital Discharge	Unfractionated Heparin	279.43	Standard Deviation 267.98	hours
Time to Hospital Discharge	Standard of Care	127.31	Standard Deviation 137.70	hours
Duration of Hypoxemia Assessed by Arterial Oxygen Saturation	Unfractionated Heparin	117.62	Standard Deviation 60.52	hours
Duration of Hypoxemia Assessed by Arterial Oxygen Saturation	Standard of Care	51.49	Standard Deviation 44.79	hours
Duration of Fever Assessed by Body Temperature	Unfractionated Heparin	24.90	Standard Deviation 29.69	hours
Duration of Fever Assessed by Body Temperature	Standard of Care	0	Standard Deviation 0	hours
Duration of Leukocytosis Assessed by White Blood Cell Count	Unfractionated Heparin	117.52	Standard Deviation 60.52	hours
Duration of Leukocytosis Assessed by White Blood Cell Count	Standard of Care	53.11	Standard Deviation 25.06	hours
Duration of Moderate to Severe Pain Assessed by Visual Analog Scale for Pain	Unfractionated Heparin	88.68	Standard Deviation 72.77	hours
Duration of Moderate to Severe Pain Assessed by Visual Analog Scale for Pain	Standard of Care	117.52	Standard Deviation 60.52	hours

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Unfractionated Heparin	4
Overall Study	STARTED	Standard of Care	3
Overall Study	COMPLETED	Unfractionated Heparin	4
Overall Study	COMPLETED	Standard of Care	3
Overall Study	NOT COMPLETED	Unfractionated Heparin	0
Overall Study	NOT COMPLETED	Standard of Care	0

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	epistaxis	Blood and lymphatic system disorders	Unfractionated Heparin	1	4	2
other	epistaxis	Blood and lymphatic system disorders	Standard of Care	0	3

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Unfractionated Heparin	0	4
Total, all-cause mortality	Standard of Care	0	3
Total, other adverse events	Unfractionated Heparin	1	4
Total, other adverse events	Standard of Care	0	3
Total, serious adverse events	Unfractionated Heparin	0	4
Total, serious adverse events	Standard of Care	0	3

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Unfractionated Heparin vs Standard of Care: deaths from any cause	Trial comparisons
Unfractionated Heparin vs Standard of Care: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02098993

GET https://conductscience.org/api/trials/v1/NCT02098993/registered

API reference For AI assistants